Kathryn Hassell
Concepts (534)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 46 | 2026 | 273 | 6.940 |
Why?
| | Water Pollutants, Chemical | 13 | 2022 | 228 | 2.140 |
Why?
| | Antiphospholipid Syndrome | 5 | 2023 | 32 | 1.750 |
Why?
| | Migraine Disorders | 2 | 2023 | 107 | 1.300 |
Why?
| | Anticoagulants | 8 | 2021 | 725 | 1.140 |
Why?
| | Perciformes | 5 | 2018 | 19 | 1.140 |
Why?
| | Heparin | 5 | 2011 | 254 | 1.090 |
Why?
| | Thrombocytopenia | 5 | 2014 | 208 | 1.070 |
Why?
| | Antibodies, Antiphospholipid | 4 | 2023 | 22 | 1.030 |
Why?
| | Fishes | 4 | 2021 | 110 | 1.010 |
Why?
| | Estrogens | 3 | 2016 | 371 | 0.790 |
Why?
| | Hydroxyurea | 5 | 2016 | 33 | 0.770 |
Why?
| | Hypertension, Pulmonary | 11 | 2025 | 1947 | 0.750 |
Why?
| | Pyridones | 2 | 2021 | 194 | 0.710 |
Why?
| | Disorders of Sex Development | 2 | 2018 | 39 | 0.680 |
Why?
| | Blood Transfusion | 7 | 2015 | 397 | 0.670 |
Why?
| | Hirudins | 4 | 2011 | 52 | 0.660 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 233 | 0.660 |
Why?
| | Hemoglobins | 8 | 2021 | 363 | 0.640 |
Why?
| | Testis | 2 | 2018 | 158 | 0.640 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 287 | 0.640 |
Why?
| | Caprylates | 1 | 2020 | 27 | 0.630 |
Why?
| | Alkanesulfonic Acids | 1 | 2020 | 48 | 0.610 |
Why?
| | Pyrazoles | 2 | 2021 | 490 | 0.610 |
Why?
| | Environmental Monitoring | 8 | 2025 | 373 | 0.590 |
Why?
| | Oocytes | 2 | 2021 | 177 | 0.570 |
Why?
| | Quality of Life | 6 | 2017 | 3064 | 0.550 |
Why?
| | Fluorocarbons | 1 | 2020 | 136 | 0.550 |
Why?
| | Neonatal Screening | 3 | 2020 | 174 | 0.530 |
Why?
| | Hemopexin | 3 | 2025 | 30 | 0.530 |
Why?
| | Cyprinidae | 1 | 2016 | 21 | 0.490 |
Why?
| | Pain | 5 | 2023 | 781 | 0.480 |
Why?
| | Australia | 10 | 2022 | 287 | 0.480 |
Why?
| | beta-Thalassemia | 2 | 2025 | 36 | 0.420 |
Why?
| | Pain Measurement | 3 | 2017 | 556 | 0.420 |
Why?
| | Embryo, Nonmammalian | 2 | 2019 | 168 | 0.410 |
Why?
| | Health Status Indicators | 1 | 2014 | 161 | 0.410 |
Why?
| | Surveys and Questionnaires | 4 | 2017 | 5994 | 0.400 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 132 | 0.400 |
Why?
| | Tricuspid Valve Insufficiency | 3 | 2011 | 26 | 0.380 |
Why?
| | Humans | 77 | 2026 | 142526 | 0.370 |
Why?
| | Adult | 41 | 2025 | 39715 | 0.370 |
Why?
| | Peptide Fragments | 4 | 2014 | 697 | 0.360 |
Why?
| | Antithrombins | 2 | 2011 | 69 | 0.350 |
Why?
| | Sewage | 2 | 2025 | 34 | 0.350 |
Why?
| | Empirical Research | 1 | 2011 | 22 | 0.340 |
Why?
| | Thrombosis | 4 | 2021 | 399 | 0.340 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 721 | 0.330 |
Why?
| | Nomograms | 1 | 2011 | 58 | 0.330 |
Why?
| | Male | 47 | 2025 | 70910 | 0.320 |
Why?
| | Censuses | 1 | 2010 | 35 | 0.320 |
Why?
| | Endocrine Disruptors | 3 | 2016 | 42 | 0.310 |
Why?
| | Animals | 28 | 2025 | 37697 | 0.310 |
Why?
| | Female | 43 | 2025 | 76624 | 0.300 |
Why?
| | Vitellogenins | 3 | 2016 | 11 | 0.300 |
Why?
| | Rivaroxaban | 2 | 2025 | 269 | 0.300 |
Why?
| | Heme | 3 | 2025 | 82 | 0.290 |
Why?
| | Health Priorities | 1 | 2009 | 43 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2025 | 337 | 0.290 |
Why?
| | Thrombophilia | 3 | 2007 | 90 | 0.290 |
Why?
| | Young Adult | 18 | 2025 | 13878 | 0.280 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2008 | 15 | 0.280 |
Why?
| | Estuaries | 2 | 2021 | 2 | 0.270 |
Why?
| | Self Care | 1 | 2010 | 387 | 0.270 |
Why?
| | Gonads | 2 | 2018 | 23 | 0.270 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2005 | 60 | 0.260 |
Why?
| | Stroke | 3 | 2021 | 1209 | 0.260 |
Why?
| | Population Surveillance | 2 | 2010 | 485 | 0.260 |
Why?
| | Nitric Oxide | 2 | 2018 | 896 | 0.260 |
Why?
| | Sickle Cell Trait | 2 | 2018 | 13 | 0.260 |
Why?
| | Hospitalists | 1 | 2011 | 245 | 0.260 |
Why?
| | Fresh Water | 3 | 2020 | 57 | 0.260 |
Why?
| | Middle Aged | 25 | 2025 | 35049 | 0.250 |
Why?
| | Haptoglobins | 2 | 2018 | 59 | 0.250 |
Why?
| | Biodiversity | 2 | 2021 | 421 | 0.250 |
Why?
| | Kinetics | 2 | 2020 | 1626 | 0.250 |
Why?
| | Phospholipids | 1 | 2008 | 211 | 0.240 |
Why?
| | Insecta | 1 | 2006 | 73 | 0.240 |
Why?
| | Estradiol | 4 | 2016 | 524 | 0.240 |
Why?
| | Acoustics | 1 | 2026 | 50 | 0.240 |
Why?
| | Environmental Pollutants | 2 | 2019 | 162 | 0.240 |
Why?
| | Fats | 1 | 2025 | 18 | 0.230 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 25 | 0.230 |
Why?
| | Patient Education as Topic | 1 | 2010 | 779 | 0.230 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 675 | 0.220 |
Why?
| | Iron | 3 | 2025 | 338 | 0.220 |
Why?
| | Adolescent | 20 | 2025 | 22326 | 0.220 |
Why?
| | Health Services Accessibility | 3 | 2016 | 1042 | 0.220 |
Why?
| | Hospitalization | 4 | 2025 | 2293 | 0.220 |
Why?
| | Estrone | 2 | 2016 | 40 | 0.220 |
Why?
| | Spleen | 2 | 2025 | 515 | 0.220 |
Why?
| | Hypertrichosis | 1 | 2023 | 8 | 0.200 |
Why?
| | Cadmium | 2 | 2021 | 68 | 0.200 |
Why?
| | Hemoglobinopathies | 1 | 2023 | 5 | 0.200 |
Why?
| | Factor Xa Inhibitors | 1 | 2025 | 188 | 0.190 |
Why?
| | Acromegaly | 1 | 2023 | 16 | 0.190 |
Why?
| | Antisickling Agents | 2 | 2016 | 7 | 0.190 |
Why?
| | Wetlands | 2 | 2022 | 30 | 0.190 |
Why?
| | Headache | 2 | 2023 | 153 | 0.190 |
Why?
| | Limb Deformities, Congenital | 1 | 2023 | 21 | 0.190 |
Why?
| | Hemostasis | 2 | 2007 | 100 | 0.190 |
Why?
| | Bays | 3 | 2017 | 7 | 0.190 |
Why?
| | Lung | 3 | 2025 | 4078 | 0.190 |
Why?
| | Child | 20 | 2024 | 22562 | 0.190 |
Why?
| | Psychometrics | 3 | 2016 | 737 | 0.190 |
Why?
| | Pesticides | 1 | 2022 | 63 | 0.180 |
Why?
| | Volatile Organic Compounds | 1 | 2023 | 63 | 0.180 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2927 | 0.180 |
Why?
| | Recombinant Proteins | 4 | 2011 | 1364 | 0.180 |
Why?
| | Mass Screening | 1 | 2011 | 1325 | 0.180 |
Why?
| | Hemolysis | 4 | 2021 | 208 | 0.180 |
Why?
| | Arginine | 2 | 2015 | 259 | 0.180 |
Why?
| | Metallothionein | 1 | 2021 | 25 | 0.170 |
Why?
| | Arterial Occlusive Diseases | 1 | 2021 | 89 | 0.170 |
Why?
| | alpha-Thalassemia | 1 | 2020 | 5 | 0.170 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2021 | 81 | 0.170 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.170 |
Why?
| | Acute Pain | 1 | 2021 | 54 | 0.160 |
Why?
| | Fertility Preservation | 1 | 2021 | 53 | 0.160 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2021 | 67 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 160 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 491 | 0.160 |
Why?
| | Infertility, Female | 1 | 2021 | 110 | 0.160 |
Why?
| | Ecotoxicology | 1 | 2019 | 3 | 0.160 |
Why?
| | Partial Thromboplastin Time | 2 | 2011 | 52 | 0.160 |
Why?
| | Vascular Remodeling | 2 | 2019 | 197 | 0.160 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 28 | 0.160 |
Why?
| | Clove Oil | 1 | 2019 | 1 | 0.150 |
Why?
| | Eugenol | 1 | 2019 | 4 | 0.150 |
Why?
| | Aged | 11 | 2025 | 25117 | 0.150 |
Why?
| | Iron Chelating Agents | 2 | 2011 | 19 | 0.150 |
Why?
| | Cyprinodontiformes | 1 | 2019 | 5 | 0.150 |
Why?
| | Multiple Organ Failure | 2 | 2005 | 127 | 0.150 |
Why?
| | Iron Overload | 2 | 2011 | 18 | 0.150 |
Why?
| | Benzoates | 2 | 2011 | 49 | 0.150 |
Why?
| | Exercise Tolerance | 2 | 2011 | 283 | 0.150 |
Why?
| | Liver | 3 | 2025 | 1848 | 0.150 |
Why?
| | Unrelated Donors | 1 | 2019 | 38 | 0.150 |
Why?
| | Prospective Studies | 9 | 2025 | 7862 | 0.150 |
Why?
| | Plastics | 1 | 2019 | 48 | 0.150 |
Why?
| | Hemorrhage | 2 | 2021 | 798 | 0.150 |
Why?
| | Altitude | 3 | 2018 | 478 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3362 | 0.140 |
Why?
| | Signal Transduction | 2 | 2013 | 5163 | 0.140 |
Why?
| | Anesthetics | 1 | 2019 | 98 | 0.140 |
Why?
| | Triazoles | 2 | 2011 | 166 | 0.140 |
Why?
| | Lipids | 2 | 2023 | 687 | 0.140 |
Why?
| | Europe | 2 | 2016 | 410 | 0.140 |
Why?
| | Practice Guidelines as Topic | 3 | 2015 | 1552 | 0.130 |
Why?
| | Bone Marrow Transplantation | 1 | 2019 | 292 | 0.130 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 273 | 0.130 |
Why?
| | Aspirin | 1 | 2021 | 396 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 209 | 0.130 |
Why?
| | Lipoproteins | 1 | 2018 | 163 | 0.130 |
Why?
| | Factor Analysis, Statistical | 2 | 2016 | 299 | 0.130 |
Why?
| | Climate Change | 1 | 2019 | 191 | 0.130 |
Why?
| | Prevalence | 4 | 2024 | 2817 | 0.130 |
Why?
| | Cohort Studies | 7 | 2018 | 5858 | 0.130 |
Why?
| | Pulmonary Artery | 4 | 2019 | 1117 | 0.130 |
Why?
| | Platelet Factor 4 | 2 | 2008 | 35 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 33 | 0.130 |
Why?
| | Biomarkers | 6 | 2026 | 4207 | 0.130 |
Why?
| | Treatment Outcome | 6 | 2025 | 11298 | 0.130 |
Why?
| | Zinc | 1 | 2020 | 299 | 0.130 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 261 | 0.120 |
Why?
| | Osmeriformes | 1 | 2016 | 1 | 0.120 |
Why?
| | Carps | 1 | 2016 | 4 | 0.120 |
Why?
| | United States | 11 | 2023 | 15447 | 0.120 |
Why?
| | Hypoxia | 3 | 2019 | 1166 | 0.120 |
Why?
| | Phenylketonurias | 1 | 2016 | 15 | 0.120 |
Why?
| | Asia | 1 | 2016 | 67 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 339 | 0.120 |
Why?
| | Principal Component Analysis | 2 | 2016 | 197 | 0.120 |
Why?
| | Olfactory Perception | 1 | 2016 | 16 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2019 | 633 | 0.120 |
Why?
| | Employment | 2 | 2014 | 181 | 0.120 |
Why?
| | Metals, Heavy | 1 | 2016 | 30 | 0.120 |
Why?
| | Rivers | 1 | 2016 | 67 | 0.120 |
Why?
| | Trace Elements | 1 | 2016 | 51 | 0.120 |
Why?
| | Erythrocyte Transfusion | 2 | 2015 | 209 | 0.120 |
Why?
| | Macrophages | 2 | 2023 | 1496 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2024 | 6324 | 0.120 |
Why?
| | Anesthesia | 1 | 2019 | 250 | 0.120 |
Why?
| | Thalassemia | 1 | 2015 | 7 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 917 | 0.120 |
Why?
| | Copper | 1 | 2016 | 115 | 0.120 |
Why?
| | North America | 1 | 2016 | 307 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2021 | 16626 | 0.110 |
Why?
| | Lung Diseases | 2 | 2019 | 786 | 0.110 |
Why?
| | Splenic Infarction | 1 | 2014 | 1 | 0.110 |
Why?
| | Fatigue | 1 | 2017 | 346 | 0.110 |
Why?
| | Protein S Deficiency | 1 | 1994 | 7 | 0.110 |
Why?
| | Zebrafish | 1 | 2019 | 509 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Blood Component Removal | 1 | 2014 | 28 | 0.110 |
Why?
| | Complement Inactivator Proteins | 1 | 1994 | 40 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 186 | 0.110 |
Why?
| | Quality of Health Care | 2 | 2016 | 649 | 0.110 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 112 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 88 | 0.100 |
Why?
| | Leg Ulcer | 1 | 2013 | 4 | 0.100 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4483 | 0.100 |
Why?
| | Thromboembolism | 1 | 2014 | 126 | 0.100 |
Why?
| | Larva | 2 | 2019 | 239 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5967 | 0.100 |
Why?
| | Blood Flow Velocity | 2 | 2014 | 415 | 0.100 |
Why?
| | Ethinyl Estradiol | 1 | 2012 | 15 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 853 | 0.100 |
Why?
| | Thrombin | 2 | 2023 | 167 | 0.100 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 105 | 0.100 |
Why?
| | Venous Thrombosis | 2 | 2005 | 194 | 0.100 |
Why?
| | Sex Factors | 3 | 2019 | 2074 | 0.090 |
Why?
| | Neoplasms | 2 | 2021 | 2761 | 0.090 |
Why?
| | Societies, Medical | 1 | 2017 | 866 | 0.090 |
Why?
| | Testosterone | 1 | 2016 | 418 | 0.090 |
Why?
| | Racism | 1 | 2014 | 147 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 283 | 0.090 |
Why?
| | Preoperative Care | 2 | 2005 | 377 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 458 | 0.090 |
Why?
| | Pharmacists | 1 | 2014 | 258 | 0.090 |
Why?
| | Hemoglobin SC Disease | 3 | 1998 | 14 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 951 | 0.090 |
Why?
| | Prostheses and Implants | 2 | 2021 | 145 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2016 | 598 | 0.090 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 1123 | 0.090 |
Why?
| | Child, Preschool | 10 | 2024 | 11634 | 0.090 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 552 | 0.090 |
Why?
| | Mortality | 2 | 2012 | 362 | 0.090 |
Why?
| | Creatinine | 2 | 2014 | 494 | 0.090 |
Why?
| | Pipecolic Acids | 1 | 2011 | 26 | 0.090 |
Why?
| | Transfusion Reaction | 1 | 2011 | 62 | 0.080 |
Why?
| | Hemofiltration | 1 | 2010 | 23 | 0.080 |
Why?
| | Mice | 6 | 2025 | 18172 | 0.080 |
Why?
| | Sulfones | 1 | 2011 | 127 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 616 | 0.080 |
Why?
| | Awareness | 1 | 2010 | 102 | 0.080 |
Why?
| | Disease Progression | 4 | 2023 | 2831 | 0.080 |
Why?
| | Disease Management | 2 | 2011 | 641 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2011 | 330 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2053 | 0.070 |
Why?
| | Piperazines | 1 | 2011 | 376 | 0.070 |
Why?
| | United Kingdom | 3 | 2014 | 325 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 651 | 0.070 |
Why?
| | Career Choice | 1 | 2010 | 234 | 0.070 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 89 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 376 | 0.070 |
Why?
| | Drug Utilization Review | 1 | 2008 | 61 | 0.070 |
Why?
| | Seawater | 1 | 2008 | 31 | 0.070 |
Why?
| | Anaerobiosis | 1 | 2008 | 65 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 160 | 0.070 |
Why?
| | Pregnancy | 3 | 2005 | 7113 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1084 | 0.070 |
Why?
| | Software | 1 | 2013 | 682 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8020 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2013 | 832 | 0.070 |
Why?
| | Body Size | 1 | 2008 | 94 | 0.070 |
Why?
| | Cost of Illness | 1 | 2010 | 316 | 0.070 |
Why?
| | Community Participation | 1 | 2009 | 136 | 0.070 |
Why?
| | Depression | 1 | 2017 | 1503 | 0.070 |
Why?
| | Metabolomics | 1 | 2013 | 712 | 0.070 |
Why?
| | Lipid Peroxidation | 2 | 2018 | 158 | 0.070 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 122 | 0.070 |
Why?
| | Proteomics | 2 | 2025 | 1152 | 0.070 |
Why?
| | Deferoxamine | 1 | 2007 | 26 | 0.070 |
Why?
| | Chironomidae | 1 | 2006 | 1 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2023 | 2007 | 0.060 |
Why?
| | Sulfonamides | 1 | 2011 | 579 | 0.060 |
Why?
| | Acute Kidney Injury | 2 | 2010 | 829 | 0.060 |
Why?
| | Age Factors | 2 | 2014 | 3316 | 0.060 |
Why?
| | Environmental Exposure | 3 | 2019 | 582 | 0.060 |
Why?
| | Rhabdomyolysis | 2 | 2018 | 24 | 0.060 |
Why?
| | Algorithms | 1 | 2014 | 1791 | 0.060 |
Why?
| | Urbanization | 2 | 2016 | 28 | 0.060 |
Why?
| | Registries | 2 | 2023 | 2227 | 0.060 |
Why?
| | Social Support | 1 | 2010 | 633 | 0.060 |
Why?
| | Erythrocytes | 2 | 2026 | 701 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 141 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 7006 | 0.060 |
Why?
| | Coronary Angiography | 1 | 2008 | 318 | 0.060 |
Why?
| | Body Weight | 2 | 2021 | 997 | 0.060 |
Why?
| | Fibrinolysis | 2 | 1998 | 162 | 0.060 |
Why?
| | Oils | 1 | 2025 | 22 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 562 | 0.060 |
Why?
| | Dermatan Sulfate | 1 | 2005 | 4 | 0.060 |
Why?
| | Species Specificity | 1 | 2006 | 574 | 0.060 |
Why?
| | Factor V | 1 | 2005 | 25 | 0.060 |
Why?
| | Captopril | 1 | 2005 | 11 | 0.060 |
Why?
| | Waste Disposal, Fluid | 1 | 2025 | 53 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 35 | 0.060 |
Why?
| | Ecosystem | 2 | 2021 | 579 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1328 | 0.050 |
Why?
| | Angina, Unstable | 1 | 2005 | 78 | 0.050 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 70 | 0.050 |
Why?
| | Infant Mortality | 1 | 2005 | 122 | 0.050 |
Why?
| | Risk | 2 | 2005 | 905 | 0.050 |
Why?
| | Polysaccharides | 1 | 2005 | 88 | 0.050 |
Why?
| | Standard of Care | 1 | 2025 | 77 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2024 | 83 | 0.050 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2005 | 83 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2251 | 0.050 |
Why?
| | Chest Pain | 1 | 2005 | 96 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2008 | 893 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 391 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 100 | 0.050 |
Why?
| | Aerosols | 1 | 2025 | 179 | 0.050 |
Why?
| | Drug Combinations | 1 | 2005 | 369 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 1008 | 0.050 |
Why?
| | Alabama | 1 | 2023 | 30 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5270 | 0.050 |
Why?
| | Syndrome | 2 | 2014 | 378 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 2 | 2013 | 1353 | 0.050 |
Why?
| | Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| | ortho-Aminobenzoates | 1 | 2022 | 10 | 0.050 |
Why?
| | Risk Factors | 5 | 2018 | 10593 | 0.050 |
Why?
| | E-Selectin | 1 | 2023 | 58 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 331 | 0.050 |
Why?
| | Oxygen | 1 | 2008 | 991 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 400 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 171 | 0.050 |
Why?
| | Medical Records | 1 | 2023 | 185 | 0.050 |
Why?
| | Glycolipids | 1 | 2023 | 49 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2009 | 686 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 721 | 0.050 |
Why?
| | Agriculture | 1 | 2022 | 100 | 0.050 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1107 | 0.050 |
Why?
| | P-Selectin | 1 | 2021 | 28 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 539 | 0.040 |
Why?
| | Data Collection | 1 | 2024 | 655 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2025 | 585 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2826 | 0.040 |
Why?
| | Colorado | 3 | 2024 | 4638 | 0.040 |
Why?
| | Blood Pressure | 3 | 2018 | 1745 | 0.040 |
Why?
| | Dietary Exposure | 1 | 2021 | 7 | 0.040 |
Why?
| | Vitrification | 1 | 2021 | 6 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2021 | 12 | 0.040 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2021 | 5 | 0.040 |
Why?
| | Oogenesis | 1 | 2021 | 19 | 0.040 |
Why?
| | Phylogeography | 1 | 2021 | 58 | 0.040 |
Why?
| | Ovulation Induction | 1 | 2021 | 56 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 58 | 0.040 |
Why?
| | von Willebrand Factor | 2 | 1998 | 84 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 580 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1508 | 0.040 |
Why?
| | Monocytes | 1 | 2023 | 545 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 187 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2004 | 547 | 0.040 |
Why?
| | Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| | Cryopreservation | 1 | 2021 | 107 | 0.040 |
Why?
| | Metals | 1 | 2021 | 142 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 247 | 0.040 |
Why?
| | HIV Infections | 1 | 1994 | 3003 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2021 | 213 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 86 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3604 | 0.040 |
Why?
| | Rats | 2 | 2019 | 5585 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 328 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2878 | 0.040 |
Why?
| | Proteinuria | 1 | 2018 | 99 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2005 | 1642 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 63 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 162 | 0.030 |
Why?
| | Thrombomodulin | 1 | 1998 | 13 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 150 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2025 | 1351 | 0.030 |
Why?
| | Body Height | 1 | 2018 | 203 | 0.030 |
Why?
| | Victoria | 1 | 2017 | 19 | 0.030 |
Why?
| | Public Health Practice | 1 | 2017 | 67 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 772 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 716 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2016 | 9 | 0.030 |
Why?
| | Fish Proteins | 1 | 2016 | 12 | 0.030 |
Why?
| | Bile | 1 | 2016 | 25 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 172 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1013 | 0.030 |
Why?
| | Pilot Projects | 2 | 2016 | 1829 | 0.030 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 47 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 150 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1037 | 0.030 |
Why?
| | Polychlorinated Biphenyls | 1 | 2016 | 12 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 54 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 343 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 200 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5700 | 0.030 |
Why?
| | Community Health Services | 1 | 2017 | 234 | 0.030 |
Why?
| | Odorants | 1 | 2016 | 117 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2013 | 2828 | 0.030 |
Why?
| | Mononuclear Phagocyte System | 1 | 1995 | 10 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 1995 | 21 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 1995 | 12 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3776 | 0.030 |
Why?
| | Arginase | 1 | 2015 | 28 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 284 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 2016 | 118 | 0.030 |
Why?
| | Vitamin B 6 Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| | Amino Acids, Sulfur | 1 | 1994 | 8 | 0.030 |
Why?
| | Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| | beta 2-Glycoprotein I | 1 | 1994 | 5 | 0.030 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1994 | 6 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2014 | 52 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 217 | 0.030 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1994 | 9 | 0.030 |
Why?
| | Blood Coagulation | 1 | 1996 | 269 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 104 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 143 | 0.030 |
Why?
| | Interview, Psychological | 1 | 2014 | 97 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 113 | 0.030 |
Why?
| | Automation | 1 | 2014 | 102 | 0.030 |
Why?
| | Folic Acid Deficiency | 1 | 1994 | 49 | 0.030 |
Why?
| | Penicillins | 1 | 2014 | 59 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 390 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 147 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 66 | 0.030 |
Why?
| | Blood Platelets | 1 | 1998 | 389 | 0.030 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1994 | 80 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 448 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1995 | 0.030 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 83 | 0.030 |
Why?
| | Hematologic Tests | 1 | 1994 | 22 | 0.030 |
Why?
| | Homocysteine | 1 | 1994 | 153 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 104 | 0.030 |
Why?
| | Ownership | 1 | 2014 | 103 | 0.030 |
Why?
| | Smegmamorpha | 1 | 2013 | 6 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 438 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2015 | 364 | 0.030 |
Why?
| | Carrier Proteins | 2 | 1995 | 743 | 0.030 |
Why?
| | Personnel Selection | 1 | 2014 | 88 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2014 | 144 | 0.030 |
Why?
| | Catalase | 1 | 2013 | 134 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 81 | 0.030 |
Why?
| | Mood Disorders | 1 | 2014 | 139 | 0.020 |
Why?
| | Hemoglobin, Sickle | 1 | 2013 | 19 | 0.020 |
Why?
| | Folic Acid | 1 | 1995 | 199 | 0.020 |
Why?
| | Professional Role | 1 | 2014 | 167 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 122 | 0.020 |
Why?
| | Liver Failure, Acute | 1 | 1994 | 66 | 0.020 |
Why?
| | Brain Diseases | 1 | 1994 | 151 | 0.020 |
Why?
| | Permeability | 1 | 2013 | 166 | 0.020 |
Why?
| | Cysteine | 1 | 1994 | 210 | 0.020 |
Why?
| | Methylamines | 1 | 2013 | 40 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2014 | 274 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 30 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 530 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 376 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 515 | 0.020 |
Why?
| | Minority Groups | 1 | 2014 | 279 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 780 | 0.020 |
Why?
| | Glycoproteins | 1 | 1994 | 356 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2015 | 246 | 0.020 |
Why?
| | Social Behavior | 1 | 2014 | 289 | 0.020 |
Why?
| | Choline | 1 | 2013 | 132 | 0.020 |
Why?
| | Perioperative Care | 1 | 2014 | 233 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 914 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 372 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 293 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 73 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 584 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2867 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2008 | 3819 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 275 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 346 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2011 | 59 | 0.020 |
Why?
| | Public Health | 1 | 2016 | 561 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 822 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 199 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 323 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 198 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1284 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 857 | 0.020 |
Why?
| | Hemodynamics | 2 | 2011 | 1114 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2018 | 930 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1994 | 325 | 0.020 |
Why?
| | Purines | 1 | 2011 | 183 | 0.020 |
Why?
| | Communication | 1 | 2016 | 949 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3081 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 684 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 373 | 0.020 |
Why?
| | Pediatrics | 1 | 2017 | 1110 | 0.020 |
Why?
| | Walking | 1 | 2014 | 548 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2523 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2514 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2011 | 209 | 0.020 |
Why?
| | Pneumonia | 1 | 2015 | 643 | 0.020 |
Why?
| | Sepsis | 1 | 1995 | 634 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1458 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 623 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1496 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1866 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1678 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2007 | 10 | 0.020 |
Why?
| | Infant | 3 | 2014 | 9908 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 252 | 0.020 |
Why?
| | Calcinosis | 1 | 2008 | 238 | 0.020 |
Why?
| | Health Personnel | 1 | 2013 | 731 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2103 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 154 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2862 | 0.010 |
Why?
| | Health Services | 1 | 2007 | 116 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2081 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1772 | 0.010 |
Why?
| | Mental Disorders | 1 | 1994 | 1144 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1821 | 0.010 |
Why?
| | Program Development | 1 | 2007 | 368 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1995 | 134 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 835 | 0.010 |
Why?
| | Isotope Labeling | 2 | 1995 | 81 | 0.010 |
Why?
| | Critical Illness | 1 | 2010 | 857 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2007 | 531 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2102 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 389 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2007 | 822 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2008 | 1194 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2008 | 1229 | 0.010 |
Why?
| | Delivery of Health Care | 1 | 2007 | 952 | 0.010 |
Why?
| | Physicians | 1 | 2008 | 937 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1996 | 107 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 209 | 0.010 |
Why?
| | Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| | 4-Aminobenzoic Acid | 1 | 1995 | 8 | 0.010 |
Why?
| | Vacuoles | 1 | 1995 | 39 | 0.010 |
Why?
| | Lactobacillus | 1 | 1995 | 27 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1995 | 117 | 0.010 |
Why?
| | Reference Standards | 1 | 1995 | 181 | 0.010 |
Why?
| | Carbon Isotopes | 1 | 1995 | 143 | 0.010 |
Why?
| | Aspartic Acid | 1 | 1994 | 81 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1994 | 81 | 0.010 |
Why?
| | Deuterium | 1 | 1994 | 99 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1995 | 353 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 807 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 227 | 0.010 |
Why?
| | Cattle | 1 | 1995 | 988 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1977 | 0.000 |
Why?
| | Brain | 1 | 1994 | 2875 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|